Does Cosentyx Maintain Efficacy Over the Long Term?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, shows sustained efficacy in long-term studies up to 5 years. In the SCULPTURE extension trial for psoriasis, 78% of patients maintained PASI 75 response at 5 years with continuous dosing, dropping to 65% for re-treated patients.[1] For psoriatic arthritis in the FUTURE 5 trial extension, 72% achieved ACR20 at 2 years, with similar rates holding through year 4.[2] Ankylosing spondylitis data from MEASURE 1/2 extensions report 60-70% maintaining ASAS40 at 5 years.[3] Efficacy holds across indications without major tachyphylaxis, though ~10-20% annual dropout occurs due to loss of response or adverse events.
What Happens to Response Rates After 5 Years?
Data beyond 5 years is limited; pooled analyses from 10,000+ patients show ~80% PASI 90 achievement at 1 year stabilizing at 70-75% through year 10 in some registries, but real-world adherence drops efficacy to 50-60%.[4] No large-scale 10+ year trials exist, as Cosentyx launched in 2015.
How Does Long-Term Use Affect Safety?
Consistent efficacy links to cumulative risks. Long-term trials report serious infections in 2-3% per year (higher than placebo), IBD flares in 1-2% (especially Crohn's history), and candida infections in 3-5%.[1][2] No increased malignancy signal over 5 years (SIR 0.9), but monitoring continues. Bone density holds stable, unlike TNF inhibitors.[3] Patient registries flag fatigue and injection reactions as common discontinuation reasons.
Why Do Some Patients Lose Response Over Time?
Primary non-response (15-20%) or secondary loss (5-10% yearly) ties to anti-drug antibodies in 5-10% of users, neutralizing efficacy.[4] Switching to IL-23 inhibitors like guselkumab restores response in 50-70% of cases.
How Does Cosentyx Compare Long-Term to Humira or Stelara?
Cosentyx outperforms Humira in 5-year psoriasis PASI 90 retention (65% vs. 50%) but matches Stelara (~70%).[1][5] In arthritis, it edges TNFs in radiographic progression halt but has higher IBD risk.[2]
[1]: PubMed - SCULPTURE 5-year data
[2]: PubMed - FUTURE 5 extension
[3]: PubMed - MEASURE long-term
[4]: Novartis Cosentyx prescribing info
[5]: PubMed - Head-to-head psoriasis meta-analysis